Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Single Session of MR Coronary Angiography and Myocardial Perfusion Imaging  Using a New Blood Pool Compound B-22956 (Gadoc...
POSITIVE NON DIAGNOSTIC POSITIVE NON DIAGNOSTIC Diagnostic Decision Tree  for Coronary Artery Disease ~ 4.4 m  procedures/...
Advantages of Cardiac MRI <ul><li>No radiation and minimal invasiveness (IV injection) </li></ul><ul><li>3-dimensional ana...
Challenges of Cardiac MRI <ul><li>Prone to cardiac and respiratory motions </li></ul><ul><li>Low signal-to-noise ratio </l...
New Experimental Contrast for  MR Coronary Angiography:  B-22956/1 <ul><li>Low molecular weight Gd chelate with very high ...
MPR Images (Siemens Symphony 1.5T) after 0.125 mmol/kg  Injection of  B-22956/1   [ Res. : 0.7    0.7    0.7 mm 3 ] 1 mi...
Res. :  1.0    1.0    2.0 (1.0)  mm 3 Volume Rendering 3D MR Coronary Angiography in Pigs  after  B-22956/1  (0.1 mmol/k...
B-22956/1   0.02 mmol/kg 2.7 s 6.4 s 9.1 s 16.4 s 20.0  s 23.6  s Conventional Gadolinium (FDA approved MRI contrast agent...
Materials and Methods <ul><li>Six Yucatan mini-swine (mean weight = 18 kg) </li></ul><ul><li>Coronary balloon angioplasty ...
Pig 2: LCx,  Mild Stenosis < 50% LCx LAD X-ray 50-70% Post-BH Post-NAV
Pig 2: RCA,  Moderate Stenosis 50-70% 50-70% X-ray Post-BH Post-NAV
Pig 1: RCA,  High Grade Stenosis > 95% RCA X-ray RCA Post-NAV
Pig 1: RCA,  Perfusion   High Grade Stenosis > 95% Low Perfusion in RCA Normal Perfusion in LAD LV RV LAD RCA
Results <ul><li>Breath-hold and high-resolution navigator-echo gated scans could repeat after the contrast injection </li>...
Conclusions <ul><li>Availability of  B-22956/1  will greatly facilitate the successful  development  of Magnetic Resonance...
Upcoming SlideShare
Loading in …5
×

Single Session of MR Coronary Angiography and Myocardial Perfusion Imaging

1,115 views

Published on

Presented by:
Jie Zheng, Debiao Li, Fabio Maggioni,
Dana Abendschein, Orlando Simonetti, Gerhard Laub,
J Paul Finn, Robert J Gropler, Friedrich M Cavagna

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

Single Session of MR Coronary Angiography and Myocardial Perfusion Imaging

  1. 1. Single Session of MR Coronary Angiography and Myocardial Perfusion Imaging Using a New Blood Pool Compound B-22956 (Gadocoletic Acid): Initial Experience in a Porcine Model of Coronary Artery Disease Jie Zheng, Debiao Li, Fabio Maggioni, Dana Abendschein, Orlando Simonetti, Gerhard Laub, J Paul Finn, Robert J Gropler, Friedrich M Cavagna Zheng J et al, Investigative Radiology 2005;40:604-613
  2. 2. POSITIVE NON DIAGNOSTIC POSITIVE NON DIAGNOSTIC Diagnostic Decision Tree for Coronary Artery Disease ~ 4.4 m procedures/y Stress ECG Ultrasound $ 400.- rule out CAD medication Stress Perfusion Imaging Nuclear Medicine rule out CAD medication ~ 2.2 m procedures/y X-Ray Coronary Angiography or IVUS $ 300.- ~ 13 m procedures/y Radiation Invasive NEGATIVE NEGATIVE $ 700.- >$ 3,000.-
  3. 3. Advantages of Cardiac MRI <ul><li>No radiation and minimal invasiveness (IV injection) </li></ul><ul><li>3-dimensional anatomic images (3D coronary artery and myocardial imaging) </li></ul><ul><li>Comprehensive functional imaging - Myocardial mechanical work </li></ul><ul><li>- Myocardial perfusion </li></ul><ul><li>- Myocardial oxygenation </li></ul><ul><li>- Myocardial Viability </li></ul>
  4. 4. Challenges of Cardiac MRI <ul><li>Prone to cardiac and respiratory motions </li></ul><ul><li>Low signal-to-noise ratio </li></ul><ul><li>Low spatial resolution relative to motionless organs (brain, kidney, etc) </li></ul>Intravascular or blood-pool contrast agents can potentially overcome these limitations!
  5. 5. New Experimental Contrast for MR Coronary Angiography: B-22956/1 <ul><li>Low molecular weight Gd chelate with very high </li></ul><ul><li>affinity for serum proteins : </li></ul><ul><li>Apparent longitudinal relaxivity (0.5 mM in Seronorm ® ) : </li></ul><ul><li>Binding (0.5 mM) to HSA 0.6 mM 94 % (80 %)* </li></ul><ul><li>Binding (0.5 mM) to PSA 0.6 mM 90 % (56 %)* </li></ul><ul><li>Binding (0.5 mM) to MSA 0.6 mM 92 % (81 %)* </li></ul>* data in parenthesis are for MS-325, a protein binding contrast agent undergoing Clinical Trials and FDA approval r 1 27 mM -1 ·s -1 (35 mM -1 ·s -1 )*
  6. 6. MPR Images (Siemens Symphony 1.5T) after 0.125 mmol/kg Injection of B-22956/1 [ Res. : 0.7  0.7  0.7 mm 3 ] 1 min postcontrast 33 min postcontrast 17 min postcontrast RCA
  7. 7. Res. : 1.0  1.0  2.0 (1.0) mm 3 Volume Rendering 3D MR Coronary Angiography in Pigs after B-22956/1 (0.1 mmol/kg b.w.) RCA RCA LAD LCx
  8. 8. B-22956/1 0.02 mmol/kg 2.7 s 6.4 s 9.1 s 16.4 s 20.0 s 23.6 s Conventional Gadolinium (FDA approved MRI contrast agent) ® 0.04 mmol/kg 2.4 s 5.6 s 8.0 s 14.4 s 17.6 s 20.8 s Myocardial Perfusion Imaging in Pig @ 1.5T (IR-True FISP TR/TE/  : 3.5/1.8/70°)
  9. 9. Materials and Methods <ul><li>Six Yucatan mini-swine (mean weight = 18 kg) </li></ul><ul><li>Coronary balloon angioplasty injury and atherogenic diet feeding atherosclerotic plaques in 2 or 3 coronary arteries </li></ul><ul><li>X-ray angiography prior to MR scans </li></ul><ul><li>MR precontrast coronary imaging </li></ul><ul><li>Injection of 0.1 or 0.15 mmol/kg B-22956/1 (Bracco) </li></ul><ul><li>MR postcontrast scans (breath-holds (BH) and navigator-echo gated imaging (NAV)) </li></ul>
  10. 10. Pig 2: LCx, Mild Stenosis < 50% LCx LAD X-ray 50-70% Post-BH Post-NAV
  11. 11. Pig 2: RCA, Moderate Stenosis 50-70% 50-70% X-ray Post-BH Post-NAV
  12. 12. Pig 1: RCA, High Grade Stenosis > 95% RCA X-ray RCA Post-NAV
  13. 13. Pig 1: RCA, Perfusion High Grade Stenosis > 95% Low Perfusion in RCA Normal Perfusion in LAD LV RV LAD RCA
  14. 14. Results <ul><li>Breath-hold and high-resolution navigator-echo gated scans could repeat after the contrast injection </li></ul><ul><li>MR Coronary Angiography results qualitatively confirmed x-ray findings in terms of stenosis degree and locations </li></ul><ul><li>Functional assessment of myocardial perfusion simultaneously </li></ul>
  15. 15. Conclusions <ul><li>Availability of B-22956/1 will greatly facilitate the successful development of Magnetic Resonance Coronary Angiography and quantification of myocardial perfusion </li></ul><ul><li>Clinical Trials are warranted to further assess the potential of this contrast agent </li></ul>

×